Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Belinostat peripheral T-cell lymphoma not applicable detail...
Unknown unknown Chidamide peripheral T-cell lymphoma not applicable detail...
Unknown unknown Copanlisib peripheral T-cell lymphoma not applicable detail...
TP53 wild-type ALRN-6924 peripheral T-cell lymphoma sensitive detail...
Unknown unknown Fenretinide peripheral T-cell lymphoma not applicable detail...
Unknown unknown Duvelisib peripheral T-cell lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01431209 Phase II Ruxolitinib Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma Active, not recruiting
NCT02181218 Phase I Pegfilgrastim romidepsin Gemcitabine + Oxaliplatin + Dexamethasone Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Recruiting
NCT02273739 Phase Ib/II Enasidenib Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated
NCT02464228 Phase II Tipifarnib Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma Recruiting
NCT02495415 Phase II Fenretinide Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas Recruiting
NCT02520791 Phase I MEDI-570 Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Recruiting
NCT02535247 Phase II Pembrolizumab Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma Active, not recruiting
NCT02567656 Phase I RP6530 Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Completed
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting
NCT02581631 Phase Ib/II Brentuximab vedotin + Nivolumab A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) Recruiting
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn
NCT02978625 Phase II Talimogene laherparepvec + Nivolumab Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting
NCT03011814 Phase Ib/II Durvalumab lenalidomide + MEDI4736 Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Recruiting
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Suspended
NCT03075553 Phase II Nivolumab Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting
NCT03161223 Phase Ib/II Durvalumab + Romidepsin Azacitidine + MEDI4736 Azacitidine + Durvalumab + Romidepsin Durvalumab + Pralatrexate + Romidepsin Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Recruiting
NCT03218683 Phase I AZD5991 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. Recruiting
NCT03240211 Phase I Pembrolizumab + Pralatrexate Decitabine + Pembrolizumab + Pralatrexate Pembrolizumab + Decitabine Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Recruiting
NCT03278782 Phase Ib/II romidepsin Romidepsin + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Recruiting
NCT03598998 Phase Ib/II Pembrolizumab + Pralatrexate Pembrolizumab and Pralatrexate in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphomas Not yet recruiting